Meritage Pharma is committed to the development of prescription products based on safe and effective molecules for the treatment of gastrointestinal and atopic diseases. Meritage Pharma’s initial product candidate is intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the esophagus.

Patents 86show all

  • 27
    A61K - Preparations for medical, dental, or toilet purposes
  • 1
    G06F - Electric digital data processing
  • 1
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data

Clinical Trials 1show all

1Phase 2

SEC Filings show all


3
D

Contact Information

San Diego, CA
United States

SEC Form D Funding Events

DateOfferedSoldType
2011-11-16$7,500,002$6,500,002Equity
2009-08-27$29,972,053$29,972,053Equity
2008-12-15Unknown Unknown Other (Paper Filing)

Key Executives

  • Elaine M. Phillips, Ph.D.
    Executive Officer, Director
  • Cam L. Garner
    Director
  • James C. Blair, Ph.D.
    Director
  • Kenneth J. Widder, M.D.
    Director
  • Adam K. Simpson
    Executive Officer
  • Malcolm R. Hill
    Executive Officer